Farrell, Michael, Shahbazi, Jeyran, Byrne, Marianne, Grebely, Jason, Lintzeris, Nicholas, Chambers, Mark, Larance, Briony, Ali, Robert, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Nicholas, Thomas, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa. Elsevier; 2022. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

Farrell, Michael, Shahbazi, Jeyran, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa, Chambers, Mark, Byrne, Marianne, Gholami, Jaleh, Zahra, Emma, Grebely, Jason, Lintzeris, Nicholas, Larance, Briony, Ali, Robert. Elsevier; 2024. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.

Shahbazi, Jeyran, Scarlett, Christopher J., Lock, Richard B., Liu, Tao, Norris, Murray D., Liu, Bing, Haber, Michelle, Tee, Andrew E., Carrier, Alice, Biankin, Aandrew V., London, Wendy B., Marshall, Glenn M.. Impact Journals LLC; 2014. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.

Settumba, Stella, Shahbazi, Jeyran, Blazey, Alison, Weiss, Robert, Dunlop, Adrian, McDonough, Michael, Cook, Jon, Farrell, Michael, Byrne, Marianne, Degenhardt, Louisa, Grebely, Jason, Larance, Briony, Nielsen, Suzanne, Lintzeris, Nicholas, Ali, Robert, Rodgers, Craig. Wiley-Blackwell; 2025. Provider costs of treating opioid dependence with extended-release buprenorphine in Australia.